Ⓐ
PeptiBrief
Endogenous neuropeptide

Vasoactive Intestinal Peptide

A 28-amino-acid endogenous neuropeptide that activates VPAC receptors and regulates vascular, pulmonary, gastrointestinal, neural and immune functions.

Sequence
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn

Evidence confidence

Human
3/5
Multiple human studies
2 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

VIP can cause flushing, headache, migraine, hypotension, tachycardia and gastrointestinal effects. Formulation and route materially affect safety.

Regulation
  • Aviptadil and VIP-based products have jurisdiction- and indication-specific regulatory status; native VIP is not a general wellness medicine.

References

  1. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial · 2021
  2. VPAC and PAC receptors: from ligands to function · 2009
  3. Inhalation of vasoactive intestinal peptide in pulmonary hypertension · 2008
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.